Delta‐9‐tetrahydrocannabinol modulates pain sensitivity among persons receiving opioid agonist therapy for opioid use disorder: A within‐subject, randomized, placebo‐controlled laboratory study
De Aquino J, Meyerovich J, Xie C, Ranganathan M, Compton P, Pittman B, Rogan M, Sofuoglu M. Delta‐9‐tetrahydrocannabinol modulates pain sensitivity among persons receiving opioid agonist therapy for opioid use disorder: A within‐subject, randomized, placebo‐controlled laboratory study. Addiction Biology 2023, 28: e13317. PMID: 37644897, PMCID: PMC10468603, DOI: 10.1111/adb.13317.Peer-Reviewed Original ResearchConceptsOpioid use disorderOpioid agonist therapyAgonist therapyMethadone dosesMethadone therapyPain sensitivityUse disordersPlacebo-controlled laboratory studySynergistic antinociceptive effectCognitive adverse effectsSingle oral dosesRisk-benefit profilePain sensitivity measuresCannabinoid receptor systemAntinociceptive effectTHC doseOral dosesOpioid agonistsAcute effectsCannabinoid agonistsPreclinical studiesAbuse potentialOpioid crisisTherapyReceptor system